Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1995 Apr;72(4):281–284. doi: 10.1136/adc.72.4.281

Liver disease in cystic fibrosis.

M S Tanner 1, C J Taylor 1
PMCID: PMC1511230  PMID: 7539244

Full text

PDF
281

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bilton D., Fox R., Webb A. K., Lawler W., McMahon R. F., Howat J. M. Pathology of common bile duct stenosis in cystic fibrosis. Gut. 1990 Feb;31(2):236–238. doi: 10.1136/gut.31.2.236. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bilton D., Fox R., Webb A. K. Liver disease and biliary tract abnormalities in cystic fibrosis. Lancet. 1990 Feb 10;335(8685):357–357. doi: 10.1016/0140-6736(90)90647-n. [DOI] [PubMed] [Google Scholar]
  3. Cohn J. A., Strong T. V., Picciotto M. R., Nairn A. C., Collins F. S., Fitz J. G. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology. 1993 Dec;105(6):1857–1864. doi: 10.1016/0016-5085(93)91085-v. [DOI] [PubMed] [Google Scholar]
  4. Colombo C., Apostolo M. G., Ferrari M., Seia M., Genoni S., Giunta A., Sereni L. P. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr. 1994 Mar;124(3):393–399. doi: 10.1016/s0022-3476(94)70361-2. [DOI] [PubMed] [Google Scholar]
  5. Colombo C., Bertolini E., Assaisso M. L., Bettinardi N., Giunta A., Podda M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr. 1993 Jun-Jul;82(6-7):562–565. doi: 10.1111/j.1651-2227.1993.tb12754.x. [DOI] [PubMed] [Google Scholar]
  6. Colombo C., Castellani M. R., Balistreri W. F., Seregni E., Assaisso M. L., Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology. 1992 Apr;15(4):677–684. doi: 10.1002/hep.1840150421. [DOI] [PubMed] [Google Scholar]
  7. Colombo C., Crosignani A., Assaisso M., Battezzati P. M., Podda M., Giunta A., Zimmer-Nechemias L., Setchell K. D. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology. 1992 Oct;16(4):924–930. doi: 10.1002/hep.1840160412. [DOI] [PubMed] [Google Scholar]
  8. Cotting J., Lentze M. J., Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut. 1990 Aug;31(8):918–921. doi: 10.1136/gut.31.8.918. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. De Arce M., O'Brien S., Hegarty J., O'Mahoney S. M., Cashman S. M., Martinez A., Delgado M., FitzGerald M. X. Deletion delta F508 and clinical expression of cystic fibrosis-related liver disease. Clin Genet. 1992 Nov;42(5):271–272. doi: 10.1111/j.1399-0004.1992.tb03254.x. [DOI] [PubMed] [Google Scholar]
  10. Dogan A. S., Conway J. J., Lloyd-Still J. D. Hepatobiliary scintigraphy in children with cystic fibrosis and liver disease. J Nucl Med. 1994 Mar;35(3):432–435. [PubMed] [Google Scholar]
  11. Donaldson P. T., Farrant J. M., Wilkinson M. L., Hayllar K., Portmann B. C., Williams R. Dual association of HLA DR2 and DR3 with primary sclerosing cholangitis. Hepatology. 1991 Jan;13(1):129–133. [PubMed] [Google Scholar]
  12. Duthie A., Doherty D. G., Williams C., Scott-Jupp R., Warner J. O., Tanner M. S., Williamson R., Mowat A. P. Genotype analysis for delta F508, G551D and R553X mutations in children and young adults with cystic fibrosis with and without chronic liver disease. Hepatology. 1992 Apr;15(4):660–664. doi: 10.1002/hep.1840150418. [DOI] [PubMed] [Google Scholar]
  13. Feigelson J., Anagnostopoulos C., Poquet M., Pecau Y., Munck A., Navarro J. Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up. Arch Dis Child. 1993 May;68(5):653–657. doi: 10.1136/adc.68.5.653. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Galabert C., Montet J. C., Lengrand D., Lecuire A., Sotta C., Figarella C., Chazalette J. P. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr. 1992 Jul;121(1):138–141. doi: 10.1016/s0022-3476(05)82561-2. [DOI] [PubMed] [Google Scholar]
  15. Gaskin K. J., Waters D. L., de Silva M., Martin H., Howman-Giles R., Dorney S. Liver disease and bileduct stenosis in cystic fibrosis. Lancet. 1990 May 5;335(8697):1098–1098. doi: 10.1016/0140-6736(90)92672-5. [DOI] [PubMed] [Google Scholar]
  16. Johansen H. K., Nir M., Høiby N., Koch C., Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet. 1991 Mar 16;337(8742):631–634. doi: 10.1016/0140-6736(91)92449-c. [DOI] [PubMed] [Google Scholar]
  17. Kitani K., Kanai S., Sato Y., Ohta M., Nokubo M. Ursodeoxycholic acid reduces the systemic toxicity of 1,2-dichloro,4-nitrobenzene by stimulating hepatic glutathione S-transferase in mice. Life Sci. 1994;54(14):983–989. doi: 10.1016/0024-3205(94)00500-1. [DOI] [PubMed] [Google Scholar]
  18. Lenzen R., Alpini G., Tavoloni N. Secretin stimulates bile ductular secretory activity through the cAMP system. Am J Physiol. 1992 Oct;263(4 Pt 1):G527–G532. doi: 10.1152/ajpgi.1992.263.4.G527. [DOI] [PubMed] [Google Scholar]
  19. Lindblad A., Hultcrantz R., Strandvik B. Bile-duct destruction and collagen deposition: a prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology. 1992 Aug;16(2):372–381. doi: 10.1002/hep.1840160215. [DOI] [PubMed] [Google Scholar]
  20. Lindor K. D., Burnes J. Ursodeoxycholic acid for the treatment of home parenteral nutrition-associated cholestasis. A case report. Gastroenterology. 1991 Jul;101(1):250–253. doi: 10.1016/0016-5085(91)90486-5. [DOI] [PubMed] [Google Scholar]
  21. Maurage C., Lenaerts C., Weber A., Brochu P., Yousef I., Roy C. C. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1989 Jul;9(1):17–20. [PubMed] [Google Scholar]
  22. McPherson M. A., Dormer R. L., Bradbury N. A., Dodge J. A., Goodchild M. C. Defective beta-adrenergic secretory responses in submandibular acinar cells from cystic fibrosis patients. Lancet. 1986 Nov 1;2(8514):1007–1008. doi: 10.1016/s0140-6736(86)92616-4. [DOI] [PubMed] [Google Scholar]
  23. McPherson M. A., Dormer R. L. Cystic fibrosis gene and mucin secretion. Lancet. 1994 Jan 1;343(8888):7–7. doi: 10.1016/s0140-6736(94)90872-9. [DOI] [PubMed] [Google Scholar]
  24. Mieles L. A., Orenstein D., Teperman L., Podesta L., Koneru B., Starzl T. E. Liver transplantation in cystic fibrosis. Lancet. 1989 May 13;1(8646):1073–1073. doi: 10.1016/s0140-6736(89)92464-1. [DOI] [PubMed] [Google Scholar]
  25. Mills C. L., Pereira M. M., Dormer R. L., McPherson M. A. An antibody against a CFTR-derived synthetic peptide, incorporated into living submandibular cells, inhibits beta-adrenergic stimulation of mucin secretion. Biochem Biophys Res Commun. 1992 Nov 16;188(3):1146–1152. doi: 10.1016/0006-291x(92)91351-p. [DOI] [PubMed] [Google Scholar]
  26. Nagel R. A., Westaby D., Javaid A., Kavani J., Meire H. B., Lombard M. G., Wise A., Williams R., Hodson M. E. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet. 1989 Dec 16;2(8677):1422–1425. doi: 10.1016/s0140-6736(89)92035-7. [DOI] [PubMed] [Google Scholar]
  27. Nakagawa M., Colombo C., Setchell K. D. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration. Hepatology. 1990 Aug;12(2):322–334. doi: 10.1002/hep.1840120221. [DOI] [PubMed] [Google Scholar]
  28. Noble-Jamieson G., Valente J., Barnes N. D., Friend P. J., Jamieson N. V., Rasmussen A., Calne R. Y. Liver transplantation for hepatic cirrhosis in cystic fibrosis. Arch Dis Child. 1994 Oct;71(4):349–352. doi: 10.1136/adc.71.4.349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. O'Brien S., Keogan M., Casey M., Duffy G., McErlean D., Fitzgerald M. X., Hegarty J. E. Biliary complications of cystic fibrosis. Gut. 1992 Mar;33(3):387–391. doi: 10.1136/gut.33.3.387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Riordan J. R. The cystic fibrosis transmembrane conductance regulator. Annu Rev Physiol. 1993;55:609–630. doi: 10.1146/annurev.ph.55.030193.003141. [DOI] [PubMed] [Google Scholar]
  31. Scott-Jupp R., Lama M., Tanner M. S. Prevalence of liver disease in cystic fibrosis. Arch Dis Child. 1991 Jun;66(6):698–701. doi: 10.1136/adc.66.6.698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Simko V., Michael S., Prego V. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis. Am J Gastroenterol. 1994 Mar;89(3):392–398. [PubMed] [Google Scholar]
  33. Strazzabosco M., Poci C., Spirlí C., Sartori L., Knuth A., Crepaldi G. Effect of ursodeoxycholic acid on intracellular pH in a bile duct epithelium-like cell line. Hepatology. 1994 Jan;19(1):145–154. [PubMed] [Google Scholar]
  34. Tanner M. S. Liver and biliary problems in cystic fibrosis. J R Soc Med. 1992;85 (Suppl 19):20–24. [PMC free article] [PubMed] [Google Scholar]
  35. Thompson G. N. Excessive fecal taurine loss predisposes to taurine deficiency in cystic fibrosis. J Pediatr Gastroenterol Nutr. 1988 Mar-Apr;7(2):214–219. doi: 10.1097/00005176-198803000-00010. [DOI] [PubMed] [Google Scholar]
  36. Weizman Z., Durie P. R., Kopelman H. R., Vesely S. M., Forstner G. G. Bile acid secretion in cystic fibrosis: evidence for a defect unrelated to fat malabsorption. Gut. 1986 Sep;27(9):1043–1048. doi: 10.1136/gut.27.9.1043. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Williams S. G., Westaby D., Tanner M. S., Mowat A. P. Liver and biliary problems in cystic fibrosis. Br Med Bull. 1992 Oct;48(4):877–892. doi: 10.1093/oxfordjournals.bmb.a072583. [DOI] [PubMed] [Google Scholar]
  38. Yang Y., Raper S. E., Cohn J. A., Engelhardt J. F., Wilson J. M. An approach for treating the hepatobiliary disease of cystic fibrosis by somatic gene transfer. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4601–4605. doi: 10.1073/pnas.90.10.4601. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. de Caestecker J. S., Jazrawi R. P., Petroni M. L., Northfield T. C. Ursodeoxycholic acid in chronic liver disease. Gut. 1991 Sep;32(9):1061–1065. doi: 10.1136/gut.32.9.1061. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES